Printer Friendly

WARNER-LAMBERT COMPANY TO MARKET COLUMBIA LABORATORIES' REPLENS: AGREEMENT SIGNED FOR LICENSE AND SUPPLY ARRANGEMENT

 WARNER-LAMBERT COMPANY TO MARKET COLUMBIA LABORATORIES' REPLENS:
 AGREEMENT SIGNED FOR LICENSE AND SUPPLY ARRANGEMENT
 HOLLYWOOD, Fla., Dec. 6 /PRNewswire/ -- Columbia Laboratories, Inc. (AMEX: COB) today announced that it has entered into a license and supply agreement under which Warner-Lambert Company has licensed the sales and marketing rights to Replens(R) in the United States and Canada. Columbia Laboratories will continue to manufacture the product, which is targeted to the many women who suffer from the discomfort of vaginal dryness. Warner-Lambert also has the opportunity to negotiate a license for other products developed by Columbia in the women's care category, based on Columbia's patented bioadhesive technology.
 "This agreement with Warner-Lambert is of major importance for Columbia," said Norman M. Meier, president and chief executive officer of Columbia. "It enables our company to benefit from the large-scale commercialization of our first major product, and to continue our development of additional products based on our patented bioadhesive technology. We are very enthusiastic about this opportunity to work with a company of Warner-Lambert's stature," Meier added.
 "We expect Replens to become one of the most important products to emerge in the feminine care market in many years," said Sara Harris, senior product manager at Warner-Lambert. "We view the product as an important addition to our product line and as an excellent vehicle to expand our franchise in women's care."
 Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company, established in 1987, dedicated primarily to developing and marketing women's care products based on its patented bioadhesive delivery system.
 -0- 12/6/91
 /CONTACT: Margaret Roell, chief financial officer of Columbia Laboratories, 305-985-6545 or Marcia A. Kean, of Feinstein Partners Inc., 617-577-8110, for Columbia Laboratories/
 (COB) CO: Columbia Laboratories ST: Florida IN: MTC SU:


KM-PB -- NE015 -- 0206 12/06/91 15:35 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 6, 1991
Words:299
Previous Article:FLEISHMAN-HILLARD NAMES WILLIAM DUKE SENIOR COUNSELOR
Next Article:USAIR REPORTS NOVEMBER TRAFFIC
Topics:


Related Articles
COLUMBIA LABORATORIES SIGNS LETTER OF INTENT TO LICENSE AND SUPPLY REPLENS AND OTHER WOMEN'S OTC HEALTH CARE PRODUCTS
WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
COLUMBIA LABORATORIES EXPANDS WORLDWIDE MARKETING OF REPLENS(R) LOGOS AGREEMENT
COLUMBIA LABORATORIES AND KODAK UNIT SIGN AGREEMENT TO EXPAND MARKETING OF REPLENS INTO JAPAN
WARNER-LAMBERT, GLAXO ANNOUNCE CONTRACT-SIGNING FOR OTC MARKETING
WARNER-LAMBERT, WELLCOME ENTER OTC JOINT VENTURE
LEUKOSITE ENTERS INTO AGREEMENT WITH WARNER-LAMBERT ON ANTI-INFLAMMATORY DRUGS
ROBERTS PHARMACEUTICAL OBTAINS EXCLUSIVE CANADIAN RIGHTS TO REPLENS FROM COLUMBIA LABORATORIES
Duramed Pharmaceuticals, Warner-Lambert Enter Into Long-Term Manufacturing Agreement
Galileo Laboratories & Warner-Lambert Sign Agreement.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters